Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J. Monk(University of Arizona Cancer Center), Andrés Poveda(Fundación Instituto Valenciano de Oncología), Ignace Vergote(KU Leuven), Francesco Raspagliesi(Fondazione IRCCS Istituto Nazionale dei Tumori), Keiichi Fujiwara(Saitama Medical University), Duk‐Soo Bae(Samsung Medical Center), Ana Oaknin(Vall d'Hebron Institute of Oncology), Isabelle Ray‐Coquard(Université Claude Bernard Lyon 1), Diane Provencher(Centre Hospitalier de l’Université de Montréal), Beth Y. Karlan(Cedars-Sinai Medical Center), Catherine Lhommé(Institut Gustave Roussy), Gary Richardson(Cabrini Hospital), Dolores Gallardo Rincón(Instituto Nacional de Cancerología), Robert L. Coleman(The University of Texas MD Anderson Cancer Center), Thomas J. Herzog(Columbia University Irving Medical Center), Christian Marth(Innsbruck Medical University), Arija Brize(Riga East University Hospital), Michel Fabbro(Institut de Recherche en Cancérologie de Montpellier), Andrés Redondo(Hospital Universitario La Paz), Aristotelis Bamias(National and Kapodistrian University of Athens), Marjan Tassoudji(Amgen (United States)), Lynn Navale(Amgen (United States)), Douglas Warner(Amgen (United States)), Amit M. Oza(Princess Margaret Cancer Centre)
Cited by 304
Abstract
Related Papers
No related papers found
Powered by citation graph analysis